Editorial board member Ian Adcock (Imperial College, London, UK) shares his views on the most challenging aspects surrounding the management of adults and children with severe asthma, as well as discussing the U-BIOPRED (Unbiased BIOmarkers in PREDiction of respiratory disease outcomes) study and promising novel therapeutic targets currently in clinical development.
Questions
1. What are the most challenging aspects of the management of adults and children with severe asthma? (0:12)
2. Could you tell us a little about the objectives of the U-BIOPRED (Unbiased BIOmarkers in PREDiction of respiratory disease outcomes) study? (0:45)
3. Of which of the study’s accomplishments are you most proud? (1:42)
4. How can the identification of phenotypes of severe asthma help in the treatment of the disease? (2:32)
5. What are the most promising novel therapeutic targets in clinical development? (3:44)
Speaker disclosure: Ian M Adcock has nothing to disclose in relation to this video interview.
Filmed at the European Respiratory Society (ERS) International Congress 2018, Paris, France, September 2018.
